News from Portfolio Companies

Four HVC's portfolio companies participate as exhibitors in the one of the largest exhibition "Bio Japan 2009" to be held Oct. 7th to 9th, 2008 at PACIFICO YOKOHAMA.

2009-10-04T08:57:33Z

Four HVC's portfolio companies participate as exhibitors in the one of the largest exhibition "Bio Japan 2009" to be held on Oct. 7th to 9th, 2008 at Pacifico Yokohama.

We look forward to seeing you at the exhibition booths and their business presentations.

Date：　Oct.7th(Wed) -9th(Fri), 2009　10：00～17：00(Tentative)
Venue：　Pacifico Yokohama (map)

Click on the names of the companies below to link to the websites.

◆GP Biosciences Ltd.

＜Seminar＞
・Date： Oct. 7th 13:30-16:30
・Venue： F-202
・Title of seminar： The Fourth Forum of Glyco-innovation and Industrial Technology
・Speaker： Masao Yamada
                 GP Biosciences Ltd.
                 Glycan Profiling System Division
                 Executive Director & CTO

◆GenoLac BL Corporation

＜Exhibition booth＞
・Booth No.：A306

＜Presentaiton＞
・Date： Oct 8th 14：00-14：20
・Venue： Business Partnering B
・Speaker：Tomomitsu Sewaki
                 President GenoLac BL Corporation
・Title：Development of Mucosal Vaccine Candidates Using a Novel Lactic acid bacteria Display System(Clinical Application for HPV Therapeutic Vaccine)

◆GLab Pathology Center Co., Ltd

＜Exhibition booth＞
・Booth No.：A703　（in the booth of Hokkaido Bio Technology Induster Cluster Forum)

＜Presentation＞
・Date：Oct 7, 14:00 - 14:20
・Venue：Business Partnering B
・Speaker：Tomohisa Maruyama
                GLab Pathology Center Co., Ltd
                Tokyo Desk, Department of Advanced Medical Research and Development
・Title：Advancement of "Personalized Medicine", "Drug Development", and "PGx" by the best use of pathology and molecular pathology technology

◆NB Health Laboratory Co.Ltd.

＜Exhibition booth＞
・Booth No.：B200　（in the booth of Yokohama/Kanagawa Pavilion）

＜Presentation＞
・Date：Oct. 7&9, 10：40-11：10
・Venue：B200　（in the booth of Yokohama/Kanagawa Pavilion）
・Speaker：NB Health Laboratory Co.Ltd.
　　　　　　　HyphaGenesis Co., Ltd
　　　　　　　PharmaDesign, Inc.

CanBas gets listed on the TSE Mothers

2009-09-17T10:04:20Z

CanBas Co., Ltd. ,one of our portfolio companies, today gets listed on the Tokyo Stock Exchanges Mothers.

＜Related Information＞
・Link to the website of CanBas Co., Ltd. is here.
・Link to the list of our portfolio companies is here.

Kringle Pharma and Maruho Agreed to Conclude an Option Agreement for ChronSeal®

2009-01-28T14:52:00Z

Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, "KRINGLE") proudly announces that it has reached to a basic agreement with Maruho Co., Ltd. (Head office located in Osaka; President & CEO: Koichi Takagi, "MARUHO") to enter into an option agreement for ChronSeal®. A multi-center phase I/II clinical trial of ChronSeal® is currently underway for the subjects with venous leg ulcers in Norway and Sweden (refer to our press releases dated 3 December 2008 and 28 January 2009).

Link to the website of press release (28 January 2009) from Kringle Pharma, Inc. is here.

Kringle Pharma Commences a Phase I/II Clinical Trial in Sweden on ChronSeal®, a Recombinant Human HGF-Based Therapy for the Treatment of Skin Ulcers

2009-01-28T14:44:35Z

Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, "KRINGLE") is proud to announce that the clinical trial application of ChronSeal® to the Swedish authority, Medical Products Agency (MPA), dated 23 December 2008 was approved on 23 January 2009. Having its approval granted by the authority, KRINGLE will conduct a phase I/II clinical trial of ChronSeal® in Sweden.

Link to the website of the press release(28 January 2009) from Kringle Pharma, Inc. is here.

CBP501 Enters Phase II Trials for the Treatment of Malignant Pleural Mesothelioma

2008-11-10T14:54:37Z

CanBas Co., Ltd. (Numazu, Shizuoka, "CanBas") and Takeda Pharmaceutical Company Limited (Osaka, "Takeda") together with its wholly-owned subsidiary Millennium: The Takeda Oncology Company (Cambridge, "Millennium") today announced the advancement of CBP501 into Phase II trials for the treatment of patients with malignant pleural mesothelioma. CBP 501 induces cancer cell death through a mechanism of action that blocks the ability of cancer cells to transition through the cell cycle. Data from the Phase I study indicates that when combined with selected chemotherapeutic drugs, CBP501 appears to enhance the anti-cancer cytotoxic activity of these established treatments.

Akiyoshi Shimamura, President of Hokkaido Wine K. K., a portfolio Company of Hokkaido VC, published a book entitled "Absolute 'Domestic Production' Policy - What the Food Maker Should Be"

2008-09-25T13:35:41Z

Mr. Akiyoshi Shimamura published a book entitled "Absolute 'Domestic Production' Policy - What the Food Maker Should Be" from TOYO KEIZAI INC. Mr. Shimamura is the president of Hokkaido Wine K. K., headquartered in Otaru, Hokkaido, which produces and distributes wine made only from domestic grapes.

-Publication Information-
Title: "Absolute 'Domestic Production' Policy - What the Food Maker Should Be"
Author: Akiyoshi Shimamura, president of Hokkaido Wine K. K.
Publisher: TOYO KEIZAI INC.
Release date: Fri., September 12, 2008
Price: JPY1,575 (including JPY75 tax)
Language: Japanese

Contents:
Chapter 1: The hidden mechanism of frequently occurred food fraud and scandals.
Chapter 2: "Phony domestic" products prevailing in wine industry.
Chapter 3: Hindrance to "domestic agricultural products."
Chapter 4: "Domestic production" policy vitalizes the region.
Chapter 5: Becoming the food maker targeting at "Domestic production."

-Related Information-
Link to the website of this publication at amazon.co.jp is here. (in English)
Link to the website of Hokkaido Wine K. K. is here. (in Japanese)

Wine produced by Hokkaido Wine K.K. was served at the G8 Hokkaido Toyako Summit 2008. Also the company's 14 wine won awards at Japan Wine Competition 2008.

2008-08-07T13:45:04Z

In the G8 Hokkaido Toyako Summit held July 7 - 9, 2008, Tsurunuma Winter Harvest Kerner 2006, a high quality sweet wine produced by Hokkaido Wine K.K., was listed in the menu for the outreach working lunch attended by the leaders on July 9th, 2008. This is the only wine produced in Hokkaido that was selected for the honorable occasion.

Also the company had an honor of their 14 wine being awarded at Japan Wine Competition 2008 held July 23 - 25, the 6th of the competition launched in 2003. The number of award-winning wine has now 79 in total, indicating increasingly high evaluation of their wine.

-Related Information-
Link to the press release from Hokkaido Wine K.K. including the list of award-winning wine is here (in Japanese).
Link to the website for Japan Wine Competition is here (in Japanese).
Link to the website of Hokkaido Wine K.K. is here (in Japanese).

Nippon Natural Resource Co., Ltd., a portfolio company of Hokkaido VC, constructs a new factory in Abashiri City.

2007-08-01T13:51:43Z

August 1, 2007, morning issue of Hokkaido Shimbun carries an article stating that Nippon Natural Resource Co., Ltd. is going to construct a factory in Abashiri City to accommodate an increased production of calcium from incinerated scallop shell. Hokkaido Venture Capital, Inc. has invested in the company through the Shinkin Regional Vitalization Fund and Hokkaido Bank "Dosanko" No. 2 Fund that it manages.

Gene Techno Science Co., Ltd., one of the Hokkaido VC's portfolio companies, announced a licensing agreement with Kaken Pharmaceutical Co., Ltd.

2007-07-04T13:56:10Z

Gene Techno Science Co., Ltd., one of the Hokkaido VC's portfolio companies, announced a licensing agreement with Kaken Pharmaceutical Co., Ltd. Hokkaido VC is the lead investor and Ikkei Matsuda, president of Hokkaido VC, is serving as a director of Gene Techno Science Co., Ltd.

Link to the press release from Gene Techno Science Co., Ltd. is here(a PDF file, 8KB).
Link to the press release from Kaken Pharmaceutical Co., Ltd. is here.